12/20/2025

Janusmed kön och genus

Janusmed kön och genus – Meropenem Mylan

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Meropenem

Meropenem

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother. 2011;17:831-41.

  2. Merrem IV (meropenem). DailyMed [www]. US National Library of Medicine. [updated 2016-07-27, cited 2016-08-17].

  3. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008;30:868-83.

  4. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46.

  5. Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Cho YH et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89-96.

  6. Mostafavi SN, Rostami S, Rezaee Nejad Y, Ataei B, Mobasherizadeh S, Cheraghi A et al. Antimicrobial Resistance in Hospitalized Patients with Community Acquired Urinary Tract Infection in Isfahan, Iran. Arch Iran Med. 2021;24(3):187-192.

  7. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.

  8. Mohammed OA, Abubakr KT, Yaghoobi A, Khdhir HH, Ali DH, Abdalrahman PK et al. Microbial prevalence and understanding of their antimicrobial susceptibility in urinary tract of patients attending at shar teaching hospital (2018-2022). BMC Res Notes. 2025;18(1):329.

  1. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother. 2011;17:831-41.
  2. Merrem IV (meropenem). DailyMed [www]. US National Library of Medicine. [updated 2016-07-27, cited 2016-08-17].
  3. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008;30:868-83.
  4. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46.
  5. Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Cho YH et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89-96.
  6. Mostafavi SN, Rostami S, Rezaee Nejad Y, Ataei B, Mobasherizadeh S, Cheraghi A et al. Antimicrobial Resistance in Hospitalized Patients with Community Acquired Urinary Tract Infection in Isfahan, Iran. Arch Iran Med. 2021;24(3):187-192.
  7. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.
  8. Mohammed OA, Abubakr KT, Yaghoobi A, Khdhir HH, Ali DH, Abdalrahman PK et al. Microbial prevalence and understanding of their antimicrobial susceptibility in urinary tract of patients attending at shar teaching hospital (2018-2022). BMC Res Notes. 2025;18(1):329.